Products & Services

The Oncotype DX Breast Recurrence Score?Test

enlightenedWhat is the Oncotype DX® test, and what makes it unique?

The Oncotype DX test reveals individual tumour biology based on measuring the expression of 21 genes1,10 The Oncotype DX Breast Recurrence Score® test has been developed for patients with early-stage HR+, HER2- breast cancer to:
 
  • Identify those patients who may benefit from chemotherapy1,2
  • Determine the magnitude of chemotherapy benefit1-5
  • Support treatment decisions1-5
 
Chemotherapy can cause both short- and long-term side effects affecting current and future health, quality of life, family life and work life.6-8 The vast majority of patients with HR+, HER2- early-stage breast cancer do not benefit from adjuvant chemotherapy.9
 
 

Prediction of chemotherapy benefit based on prospective clinical trials makes the Oncotype DX test unique.




The Oncotype DX test reveals individual tumour biology based on measuring the expression of 21 genes1,10
enlightenedGuiding treatment with the Oncotype DX test
    
For further information, please click this website  https://www.oncotypedxtest.com/




REFERENCES
1. Paik et al. J Clin Oncol. 2006.
2. Albain et al. Lancet Oncol. 2010.
3. Sparano JA et al. N Engl J Med. 2018.
4. Kalinsky. N Engl J Med. 2021.
5. Kalinsky et al. SABCS. 2021 GS2-07.
6. Partridge et al. J Natl Cancer Inst Monogr. 2001.
7. Friese et al. Cancer. 2017.
8. Groenvold. Dan Med Bull. 2010.
9. EBCTCG. Lancet. 2012.
10. Paik et al. N Engl J Med. 2004.
11. Dowsett M et al. J Clin Oncol. 2010.
12. Nitz et al. Breast Cancer Res Treat. 2017.
13. Geyer et al. NPJ Breast Cancer. 2018.
14. Ballman et al. J Clin Oncol. 2015.
15. Sparano et al. N Engl J Med. 2019.
16. Sparano et al. Abstract GS1-05, SABCS 2022.
17. Sparano and Paik. J Clin Oncol. 2008.